相关实验视频
Updated: Jun 23, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
探索民间传说厄瓜多尔药用植物及其生物活性成分,专注于抗糖尿病潜力:概述
Soham Bhattacharya1, Neha Gupta2, Adéla Flekalová2
1Department of Agroecology and Crop Production, Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague, Kamýcká 129, Prague 6, 16500 Suchdol, Czech Republic.
Plants (Basel, Switzerland)
|June 19, 2024
概括
厄瓜多尔的药用植物为糖尿病治疗提供了天然替代品. 研究发现了27种植物,其中22种具有低血糖特性,突出了民族植物学在开发新型抗糖尿病疗法的潜力.
科学领域:
- 民族植物学 民族植物学
- 药理学 药理学是指药理学的学科.
- 植物化学 植物化学
背景情况:
- 糖尿病 (DM) 是一个全球性的健康问题,目前的治疗有效性有限,系统性毒性有限.
- 由于副作用最小,人们越来越多地寻求天然的植物替代品来治疗糖尿病.
- 厄瓜多尔拥有丰富的民族植物历史,传统上使用药用植物治疗各种疾病,包括糖尿病.
研究的目的:
- 识别和探索在厄瓜多尔用于治疗糖尿病的传统药用植物.
- 审查这些植物抗糖尿病性质的生物活性植物化学物质.
- 强调需要在民族医学实践和药理学研究之间采取综合方法.
主要方法:
- 关于厄瓜多尔药用植物的民族植物学数据和科学研究的文献综述.
- 在厄瓜多尔,鉴定传统上用于治疗糖尿病的植物.
- 在体外和体内研究的分析,证明了低血糖或抗高血糖效应.
主要成果:
- 确定了27种传统上用于治疗糖尿病的厄瓜多尔药用植物.
- 其中22种植物表现出显著的低血糖或抗高血糖特性.
- 生物活性化合物如黄类,类和类被确定为抗糖尿病作用的关键贡献者.
结论:
- 厄瓜多尔的药用植物具有作为天然抗糖尿病剂的巨大潜力.
- 对于某些传统药物,如Bryophyllum gastonis-bonnieri,还需要进一步的药理阐明.
- 将民族医学知识与科学研究相结合,可以推动糖尿病天然产品开发的创新.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
170
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
170
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188

